Clinical Trials Logo

Clinical Trial Summary

The purpose of this randomized and placebo-controlled EpoRepair trial is to evaluate the effect of intravenously administered recombinant human erythropoietin (Epo) as compared to placebo in preterm infants with brain damage on neurological development until five years od age.


Clinical Trial Description

Worldwide, 1% of all infants are born very preterm with less than 32 weeks of gestation, which is more than 2 months before expected date of delivery. If these smallest infants suffer in addition to prematurity a second hit, such as intraventricular hemorrhage or parenchymal infarction, they are at high risk for learning disabilities, mental retardation, and cerebral palsy in later life.

Intraventricular hemorrhage and parenchymal infarction occur in about 12% of very preterm infants, mostly in the very smallest and within the first few days after birth, and can be recorded by cranial ultrasound. Except for shunt insertion to divert cerebrospinal fluid in infants with posthemorrhagic hydrocephalus and possibly the removal of blood clots, there is no treatment for established intracerebral bleeding, and no medical therapies exist to ameliorate the neurodevelopmental sequelae.

Apart from stimulating production of red blood cells in the bone marrow, recombinant human erythropoietin (Epo) has been shown to exert neuroprotective action in a variety of animal models and in clinical studies. Epo administration has been found to be beneficial and safe in randomized controlled trials (RCT) involving adult and infant patients.

Observational data suggest that Epo administered to very preterm infants in order to prevent from anemia improves long-term cognitive outcomes until school-age especially in those infants who had suffered intracerebral bleeding. These data, however, are observational and therefore do not allow for any firm conclusions or recommendations. The hypothesis generated by these data calls for confirmation or refutation by an RCT designed to address this question. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02076373
Study type Interventional
Source University of Zurich
Contact
Status Active, not recruiting
Phase Phase 3
Start date March 2014
Completion date March 2024

See also
  Status Clinical Trial Phase
Completed NCT05844709 - Effectiveness of Nursing Care Bundle for the Prevention of Intraventricular Hemorrhage in Preterm Infants
Completed NCT02147769 - Cerebral Oxygenation and Autoregulation in Preterm Infants
Withdrawn NCT03390530 - Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage Phase 3
Terminated NCT01482559 - Management of Hypotension In the Preterm Infant Phase 3
Recruiting NCT06280872 - Physiologically Based Cord Clamping To Improve Neonatal Outcomes In Moderate And Late Preterm Newborns N/A
Terminated NCT03543046 - Tortle Midliner and Intraventricular Hemorrhage N/A
Recruiting NCT05617833 - Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage Phase 1